These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 16265371)

  • 41. Clinical characteristics and outcomes of patients with angina and heart failure in the CHARM (Candesartan in Heart Failure Assessment of Reduction in Mortality and Morbidity) Programme.
    Badar AA; Perez-Moreno AC; Hawkins NM; Brunton AP; Jhund PS; Wong CM; Solomon SD; Granger CB; Yusuf S; Pfeffer MA; Swedberg K; Gardner RS; Petrie MC; McMurray JJ
    Eur J Heart Fail; 2015 Feb; 17(2):196-204. PubMed ID: 25678097
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Impact of diabetes on outcomes in patients with low and preserved ejection fraction heart failure: an analysis of the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) programme.
    MacDonald MR; Petrie MC; Varyani F; Ostergren J; Michelson EL; Young JB; Solomon SD; Granger CB; Swedberg K; Yusuf S; Pfeffer MA; McMurray JJ;
    Eur Heart J; 2008 Jun; 29(11):1377-85. PubMed ID: 18413309
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Effect of valsartan on systemic right ventricular function: a double-blind, randomized, placebo-controlled pilot trial.
    van der Bom T; Winter MM; Bouma BJ; Groenink M; Vliegen HW; Pieper PG; van Dijk AP; Sieswerda GT; Roos-Hesselink JW; Zwinderman AH; Mulder BJ
    Circulation; 2013 Jan; 127(3):322-30. PubMed ID: 23247302
    [TBL] [Abstract][Full Text] [Related]  

  • 44. [CHARM study--new strategy for the treatment of heart failure].
    Hasegawa H; Komuro I
    Nihon Rinsho; 2004 May; 62(5):995-1002. PubMed ID: 15148833
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Clinical outcomes according to baseline blood pressure in patients with a low ejection fraction in the CHARM (Candesartan in Heart Failure: Assessment of Reduction in Mortality and Morbidity) Program.
    Meredith PA; Ostergren J; Anand I; Puu M; Solomon SD; Michelson EL; Olofsson B; Granger CB; Yusuf S; Swedberg K; Pfeffer MA; McMurray JJ
    J Am Coll Cardiol; 2008 Dec; 52(24):2000-7. PubMed ID: 19055992
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Influence of nonfatal hospitalization for heart failure on subsequent mortality in patients with chronic heart failure.
    Solomon SD; Dobson J; Pocock S; Skali H; McMurray JJ; Granger CB; Yusuf S; Swedberg K; Young JB; Michelson EL; Pfeffer MA;
    Circulation; 2007 Sep; 116(13):1482-7. PubMed ID: 17724259
    [TBL] [Abstract][Full Text] [Related]  

  • 47. [Cardioprotection by means of Candesartan in cardiac insufficiency. CHARM overall partial evaluation (Candesartan in heart failure assessment of reduction in mortality and morbidity)].
    Tschöpe C; Schultheiss HP
    Internist (Berl); 2006 Oct; 47(10):1084-6. PubMed ID: 16988804
    [No Abstract]   [Full Text] [Related]  

  • 48. Prevention of atrial fibrillation in patients with symptomatic chronic heart failure by candesartan in the Candesartan in Heart failure: assessment of Reduction in Mortality and morbidity (CHARM) program.
    Ducharme A; Swedberg K; Pfeffer MA; Cohen-Solal A; Granger CB; Maggioni AP; Michelson EL; McMurray JJ; Olsson L; Rouleau JL; Young JB; Yusuf S
    Am Heart J; 2006 May; 151(5):985-91. PubMed ID: 16644318
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Sex differences in clinical characteristics and prognosis in a broad spectrum of patients with heart failure: results of the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) program.
    O'Meara E; Clayton T; McEntegart MB; McMurray JJ; Piña IL; Granger CB; Ostergren J; Michelson EL; Solomon SD; Pocock S; Yusuf S; Swedberg K; Pfeffer MA;
    Circulation; 2007 Jun; 115(24):3111-20. PubMed ID: 17562950
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Beta blockers in systolic heart failure: do physicians need more courage?
    Yilmaz MB; Refiker M
    Am Heart J; 2007 Nov; 154(5):e23; author reply e25. PubMed ID: 17967570
    [No Abstract]   [Full Text] [Related]  

  • 51. Prognostic Value of Insulin-Like Growth Factor-Binding Protein 7 in Patients with Heart Failure and Preserved Ejection Fraction.
    Gandhi PU; Chow SL; Rector TS; Krum H; Gaggin HK; McMurray JJ; Zile MR; Komajda M; McKelvie RS; Carson PE; Januzzi JL; Anand IS
    J Card Fail; 2017 Jan; 23(1):20-28. PubMed ID: 27317843
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Chronic heart failure: an overview of conventional treatment versus novel approaches.
    Landmesser U; Drexler H
    Nat Clin Pract Cardiovasc Med; 2005 Dec; 2(12):628-38. PubMed ID: 16306919
    [TBL] [Abstract][Full Text] [Related]  

  • 53. A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure.
    Cohn JN; Tognoni G;
    N Engl J Med; 2001 Dec; 345(23):1667-75. PubMed ID: 11759645
    [TBL] [Abstract][Full Text] [Related]  

  • 54. The CHARM programme.
    Pechlaner C
    Lancet; 2003 Nov; 362(9396):1675-6; author reply 1678-9. PubMed ID: 14630453
    [No Abstract]   [Full Text] [Related]  

  • 55. A review of the current evidence for the use of angiotensin-receptor blockers in chronic heart failure.
    Erhardt LR
    Int J Clin Pract; 2005 May; 59(5):571-8. PubMed ID: 15857354
    [TBL] [Abstract][Full Text] [Related]  

  • 56. [AT1 blockers against heart failure. The charm of polypharmacy].
    MMW Fortschr Med; 2003 Sep; 145(38):6. PubMed ID: 14603670
    [No Abstract]   [Full Text] [Related]  

  • 57. Proteinuria, chronic kidney disease, and the effect of an angiotensin receptor blocker in addition to an angiotensin-converting enzyme inhibitor in patients with moderate to severe heart failure.
    Anand IS; Bishu K; Rector TS; Ishani A; Kuskowski MA; Cohn JN
    Circulation; 2009 Oct; 120(16):1577-84. PubMed ID: 19805651
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Carvedilol improves left ventricular function and symptoms in chronic heart failure: a double-blind randomized study.
    Olsen SL; Gilbert EM; Renlund DG; Taylor DO; Yanowitz FD; Bristow MR
    J Am Coll Cardiol; 1995 May; 25(6):1225-31. PubMed ID: 7722114
    [TBL] [Abstract][Full Text] [Related]  

  • 59. CHARMed - the effects of candesartan in heart failure.
    Doggrell SA
    Expert Opin Pharmacother; 2005 Mar; 6(3):513-6. PubMed ID: 15794741
    [No Abstract]   [Full Text] [Related]  

  • 60. Angiotensin receptor blockers in patients with heart failure and a reduced left ventricular ejection fraction. Implications of the HEAAL trial.
    Pitt B
    Pol Arch Med Wewn; 2010 Mar; 120(3):68-70. PubMed ID: 20332711
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.